Enantiomeric drug development: Issues, considerations, and regulatory requirements
Authors:
- 1 September 2001
- journal article
- case report
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 90 (9) , 1205-1215
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 InhibitionClinical Pharmacokinetics, 2000
- Effect of oxybutynin on the QTc interval in elderly patients with urinary incontinenceBritish Journal of Clinical Pharmacology, 1996
- Pharmacodynamic and Stereoselective Pharmacokinetic Interactions between Zileuton and Warfarin in HumansClinical Pharmacokinetics, 1995
- Chirality in New Drug DevelopmentClinical Pharmacokinetics, 1994
- The pharmacological effect of citalopram resides in the (S)-(+)-enantiomerJournal of Neural Transmission, 1992
- Racemic mixtures and single stereoisomers: Industrial concerns and issues in drug developmentChirality, 1991
- Dilevalol: A Selective Beta‐2 Adrenergic Agonist Vasodilator with Beta Adrenergic Blocking ActivityThe Journal of Clinical Pharmacology, 1989
- Stereoselective Interaction of Omeprazole with Warfarin in Healthy MenTherapeutic Drug Monitoring, 1989
- Pharmacodynamic modeling of the EEG effects of ketamine and its enantiomers in manJournal of Pharmacokinetics and Biopharmaceutics, 1987
- Importance of Drug Enantiomers in Clinical PharmacologyDrugs, 1985